INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

Introduction: the need for advanced monitoring in shake flasks. Shake flasks have been a cornerstone of biotechnological ...

Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) ...

OTR has been used for microbial fermentation but is difficult to measure accurately with conventional methods for mammalian cell cultivation.

CEPI is providing US$4.5 million to non-profit Fondazione Biotecnopolo di Siena (FBS) for proof-of-concept research that will ...

Global Large and Small Scale Bioprocessing Market is valued at approximately USD 57.08 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 14.21% over the forecast ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8534 ...

Operator Good afternoon, ladies and gentlemen, and welcome to the INOVIO Pharmaceuticals fourth quarter 2024 financial results conference call. At this time, all lines are in listen-only mode.

Inovio Pharmaceuticals Inc (INO) addresses manufacturing issues and progresses towards BLA submission, despite financial ...

Type 1, not type 2 diabetes, is autoimmune. There are other rarer autoimmune types. Learn about type 2 diabetes, immunity, ...

Dr. Ashish K. Jha is dean of Brown University School of Public Health and a contributing Globe Opinion writer.

Inovio plans to begin submitting the BLA for INO-3107 in mid-2025, with a goal of achieving FDA acceptance for filing by year-end 2025. Priority review will also be requested.